苯磺酸左旋氨氯地平联合厄贝沙坦治疗高血压合并蛋白尿的临床观察

Efficacy Observation of Levoamlodipine Besylate Combined with Irbesartan in the Treatment of Hypertension and Proteinuria

目的:观察苯磺酸左旋氨氯地平联合厄贝沙坦治疗原发性高血压合并蛋白尿的疗效。方法:将120例原发性高血压合并蛋白尿患者随机均分为2组,治疗组60例给予苯磺酸左旋氨氯地平2.5mg.d-1+厄贝沙坦150mg.d-1治疗;对照组60例给予硝苯地平缓释片10mg,bid+厄贝沙坦150mg.d-1治疗。2组均连续用药90d。比较2组患者的血压和尿蛋白水平,观察2组患者的不良反应发生情况。结果:治疗后,2组患者的血压和尿蛋白水平均显著低于治疗前,且治疗组降压效果显著优于对照组(P<0.05),尿蛋白显著少于对照组(P<0.05)。2组治疗过程中均有少数患者出现不良反应,但差异无统计学意义(P>0.05)。结论:苯磺酸左旋氨氯地平联合厄贝沙坦治疗高血压合并蛋白尿患者,不但能更有效控制高血压,还能更有效保护肾功能。

OBJECTIVE： To observe the effects of levoamlodipine besylate combined with irbesartan on primary hypertension and proteinuria. METHODS： 120 patients with primary hypertension and proteinuria were divided randomly into 2 groups. 60 patients in treatment group were given levoamlodipine besylate 2.5 mg.d-1 and irbesartan 150 mg. d-l, 60 patients in control group were given Nifedipine sustained-release tablets 10 mg, bid and irbesartan 150 mg.d-1. Both groups were treated 90 days. The blood pressure, proteinuria and ADR in both groups were measured before and after treatment. RESULTS： The blood pressure and pro- teinuria of 2 groups after treatment were significantly lower than before treatment, lowering pressure effect of treatment group was better than control group, there was statistical significance （P〈0.05）, proteinuria level of treatment group was lower than that of control group （P〈0.05）. ADR was found in 2 groups during treatment, but there was no statistical significance. CONCLUSION： The therapy of levoamlodipine besylate combined with irbesartan not only control blood pressure effectively, hut also protect renal function of patients with primary hypertension and proteinuria.